# Kendall Square & Cambridge Growth Trajectory

## Employment Growth

**Current Employment:**
- Kendall Square: ~50,000 daily workers
- Cambridge overall: ~137,000 total workforce
- Top 25 employers represent ~59,000 FTEs (43% of workforce)

**Life Sciences:**
- Massachusetts life sciences: 140,000+ jobs statewide (2024)
- Kendall Square is the epicenter
- Average salary: $200,000
- Biotech hiring: 1 in 5 new MA jobs (2014-2023)

**Major Employer Headcounts:**
| Employer | Employees |
|----------|-----------|
| MIT | 11,888 |
| Novartis | 2,000+ |
| Moderna | 1,738 (2021) |
| Biogen | Major (580K sq ft new HQ) |

**Recent Trends:**
- Biotech workforce grew 2.6% to ~117,000 in 2023
- Life science job postings fell 30%+ between 2022-2023
- 13 biotech companies laid off 1,400 in MA in 2024

---

## Population Growth

| Year | Population | Change |
|------|------------|--------|
| 2010 | 105,162 | - |
| 2019 | 118,988 | Peak |
| 2020 | 118,403 | +12.6% from 2010 |
| 2023 | 118,214 | -0.14% from 2020 |

**Key Stats:**
- 2010-2020 growth: +13,241 people (+12.6%)
- Growth rate 73% higher than US average
- Density: 16,470 people/sq mi (2nd highest in MA)

---

## Commercial Real Estate

**Kendall Square Inventory (2024):**
- Class A: 11.3M sq ft (50 buildings)
- Class B: 2.2M sq ft (30 buildings)
- Class C: 1.4M sq ft (46 buildings)
- **Total: ~15 million sq ft**

**Lab Space:**
- Cambridge: 10.24M sq ft (96% occupied)
- Greater Boston lab space grew 57% in 2 years (2022-2024)
- 21.6M+ sq ft added statewide in last decade (+117%)

**2015 Kendall Square Urban Renewal Plan:**
- Approved 4+ million sq ft of new development
- 19+ new buildings
- 150,000 sq ft public open space
- 400,000 sq ft residential

---

## Major Employers

**Anchor Institutions:**
- Harvard University (#1 since 1986)
- MIT (#2 since 1986)

**Biotech/Pharma (7 of top 16 private employers):**
- Takeda (#3 overall)
- Moderna, Alnylam, Sarepta, Sanofi
- Novartis, Bristol Myers Squibb, AstraZeneca, Pfizer

**Tech:**
- Google, Facebook, IBM research labs
- Akamai, HubSpot, Pegasystems, CarGurus

**Biotech Concentration:**
- 250+ biotech companies in Cambridge
- 120+ within Kendall Square zip code alone

---

## Future Development Pipeline

**Kendall Common (Former Volpe Site) - 2025-2028:**
- ~3 million sq ft mixed-use
- Biogen Global HQ: 580,000 sq ft (opening 2028)
- Housing, retail, community center, parks

**585 Kendall (Takeda/BioMed Realty) - 2026:**
- 30,000 sq ft performing arts center
- 400-seat theater

**Third & Kendall Streets:**
- 500,000 sq ft, 16-story mixed-use
- Lab, office, performance center

**Infrastructure:**
- Eversource underground substation
- District-scale blackwater treatment
- Four all-electric net-zero residential buildings

---

## Economic Impact

**Venture Capital (2024):**
- MA biotech VC: $7.89 billion
- Cambridge: $2.2 billion (73 deals)
- MA = 28.3% of all US biotech VC (2nd to CA at 41.6%)

**M&A Activity (2024):**
- 32 local companies acquired for $42.6B total
- Bristol Myers Squibb acquired Karuna for $13.8B

**Regional GDP:**
- Boston-Cambridge-Newton Metro: $610.5 billion (2023)
- MA ranked #1 in US for VC investment per $1M of state GDP

---

## Implications for Transit

1. **High transit dependency** - 50,000 daily workers, limited parking, 16,470 people/sq mi density
2. **Continued growth** - 3M+ sq ft under development through 2028
3. **High-value employment** - $200K average salaries generate significant economic activity
4. **Anchor commitments** - Biogen, Takeda making long-term investments despite sector slowdown
